The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer-Reference-Cited by-同舟云学术

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Published:2021-12-15 Issue:7890 Volume:600 Page:727-730
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Janjigian Yelena Y.^ORCID,Kawazoe Akihito,Yañez Patricio,Li Ning,Lonardi Sara,Kolesnik Oleksii,Barajas Olga,Bai Yuxian,Shen Lin,Tang Yong,Wyrwicz Lucjan S.,Xu Jianming,Shitara Kohei,Qin Shukui,Van Cutsem Eric,Tabernero Josep^ORCID,Li Lie,Shah Sukrut,Bhagia Pooja,Chung Hyun Cheol

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-021-04161-3.pdf

Reference32 articles.

1. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).

2. Van Cutsem, E. et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18, 476–484 (2015).

3. Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017).

4. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010).

5. Shitara, K. et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 6, 1571–1580 (2020).

Cited by 438 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in gastrointestinal cancers: Spotlight on the pivotal role of currently available biomarkers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Immunotherapeutic strategies in gastroesophageal tumors;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

3. Tumor immune microenvironmental characteristics in Human Epidermal Growth Factor-2 (HER2) positive esophageal adenocarcinoma: A comparative analysis and biomarker study;Translational Oncology;2024-11

4. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes;Cancer Treatment Reviews;2024-11

5. Molecular mechanisms of HER2-targeted therapy and strategies to overcome the drug resistance in colorectal cancer;Biomedicine & Pharmacotherapy;2024-10